1 **Predictors of postoperative biochemical remission in acromegaly**
2

Shun Yao, MD, PhD,[1,2#] Wen-Li Chen, MD,[1#] Sherwin Tavakol, MPH,[2,3] Farhana Akter, MD[4,5]
Michael P. Catalino, MD, MSc,[2,6] Xiao-Peng Guo, MD, PhD,[7] Ai-Liang Zeng, MD, PhD,[8] Leo
Zekelman, BA,[9] Jian Song, MD, PhD,[10] Zhi-Gang Mao, MD, PhD,[1] Yong-Hong Zhu, PhD,[11]
Qing-Zhi Wu, PhD,[12] Edward R Laws, Jr, MD, FACS,[2] Wenya Linda Bi, MD, PhD, [2*] Hai-Jun
Wang, MD, PhD[1*]

[1] Center for Pituitary Tumor Surgery, Department of Neurosurgery, The First Affiliated Hospital,
Sun Yat-sen University, Guangzhou 510080, China
[2] Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and
Women's Hospital, Harvard Medical School, MA 02115, USA
[3] Department of Neurological Surgery, Keck School of Medicine, University of Southern
California, Los Angeles, CA 90033, USA
[4] Faculty of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA
[5] Department of Neuroscience, University of Cambridge, Cambridge 00000, UK
[6] Department of Neurosurgery, University of North Carolina, Chapel Hill, NC 27599, USA
[7] Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of
Medical Sciences and Peking Union Medical College, Beijing 100730, China
[8] Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston,
TX 77030, USA
[9] Speech and Hearing Bioscience and Technology, Harvard University, Cambridge, MA 02138,
USA
[10] Department of Neurosurgery, The General Hospital of Chinese PLA Central Theater
Command, Southern Medical University, Wuhan 430070, China
[11] Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-Sen
University, Guangzhou 510080, China
[12] State Key Laboratory of Advanced Technology for Materials Synthesis and Processing,
Wuhan University of Technology, Wuhan 430070, China
29

30 **Co-corresponding authors**
31
32 **Wenya Linda Bi, M.D., Ph.D.**
33 Assistant Professor
34 Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School
35 60 Fenwood Road, MA 02115, United States
36 Email: wbi@bwh.harvard.edu | Tel: +1 (617) 525-8319
37
38 **Hai-Jun Wang, M.D., Ph.D.**
39 Chairman and Professor
40 Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen University
41 58 Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, Guangdong, China
42 Email: wanghaij@mail.sysu.edu.cn | Tel: +86-138 2619 9966
43

44 **Key Words**: acromegaly, growth hormone, pituitary tumor, predictors, biochemical remission

ABSTRACT

OBJECTIVE
Acromegaly is a rare neuroendocrine condition that can lead to significant morbidity; therefore, large studies are invaluable for understanding the disease burden. Despite China's vast population size, studies on acromegaly remain sparse. In this report, we aimed to investigate clinical characteristics and predictors of biochemical remission after surgery for acromegaly.

METHODS
A retrospective nationwide study was conducted using patient-reported data from the China Acromegaly Patient Association (CAPA) from 1998 to 2018. Univariate analyses were performed using Wilcoxon rank-sum tests, two-sample t-tests, and chi-squared tests. Using the purposeful selection method, multivariate logistic regression analysis was employed to determine independent predictors of biochemical remission at 3 months in patients after surgery.

RESULTS
In total, we identified 575 patients (mean age: 37.3 years; 59% female). The most common clinical features were enlarged nose and prognathism (97%) and overgrowth of extremities (93%). The majority of the cohort comprised of macroadenomas (n=479, 83%), and invasive tumors with a Knosp score of 3-4 (n=353, 61%). Ninety-five percent of patients were treated first with surgery and 38.3% exhibited biochemical remission at 3-months postoperatively. The following independent predictors of biochemical remission were identified: preoperative growth hormone (GH) levels between 12 and 28 μg/L [odds ratio (OR)=0.61; 95% confidence interval (CI), 0.39-0.96; p=0.031], preoperative GH levels >28 μg/L (OR=0.56; 95% CI, 0.35-0.90; p=0.016), macroadenoma (OR=0.57; 95% CI, 0.33-0.97; p=0.041), giant adenomas (OR=0.17; 95% CI, 0.06-0.44; p=0.0005), Knosp score 3-4 (OR=0.39; 95% CI, 0.25-0.59; p<0.0001), and preoperative medication usage (OR=2.16; 95% CI, 1.38-3.39; p=0.0008).

CONCLUSIONS
In this nationwide study spanning over two decades, we highlight that higher preoperative GH levels, large tumor size, and greater extent of tumor invasiveness are associated with a lower likelihood of biochemical remission at 3-months after surgery, while preoperative medical therapy increases the chance of remission.

Introduction

Acromegaly is a rare condition characterized by the overproduction of growth hormone (GH) from a hypersecreting pituitary tumor.[1–3] Clinical manifestations of GH-secreting tumors can manifest insidiously and result in a delayed diagnosis, while the systemic repercussions of insulin-like growth factor 1 (IGF-1) excess, resultant from GH stimulation, are associated with increased morbidity and mortality.[4] Symptoms and signs of acromegaly include facial changes, excessive skeletal growth, soft tissue hypertrophy, obstructive sleep apnea, hyperhidrosis, headache, and visual impairments.[2,5–7] Persistent high levels of GH and/or IGF-1 may also result in glucose intolerance, osteoporosis, arthritis, reproductive disorders, and cardiovascular dysfunction, ultimately driving premature mortality.[2,4–7]

Given the rarity of acromegaly, large studies that characterize the disease pattern, describe risk factors predictive of poor disease control and inform management decisions of this condition are scarce. In particular, there is a notable gap in data regarding prevalence, disease severity, treatments administered, and clinical outcomes for acromegaly patients in China. We present the first report from the China Acromegaly Patient Association (CAPA), which is a non-profit, patient-advocacy organization with a patient-reported database encompassing treatment from 112 hospitals. Using data from this directory, we aim to provide a comprehensive description of clinical characteristics, and to identify predictors of biochemical remission at 3 months after surgery in patients with acromegaly in China, so as to improve recognition for the diagnosis of acromegaly and to guide management decisions.

Methods

Study Design and Data Collection

We retrospectively reviewed the records of 916 acromegaly patients enrolled into the multi-institutional China Acromegaly Patient Association (CAPA) database (https://capa.wohenok.com) between June 1998 and December 2018. The CAPA database is patient-reported and relies on the patient submission of demographic and clinical information following the diagnosis and treatment of acromegaly, drawing upon patient information from 112 hospitals across 23 provinces, 4 autonomous regions, 4 municipalities, and 2 Special Administrative Regions (SARs) in China (**Supplemental Materials S1**). Patients lacking data on treatment interventions or biochemical status at follow-up were excluded from the analysis, resulting in a final cohort of 575 patients.

We extracted demographic data (including age, sex, location of residence, and insurance type), disease duration, clinical symptoms, biochemical status (at diagnosis and on follow-up), radiographic features, treatment history, histopathology, postoperative complications, and follow-up at 3 months after treatment. Approval (approved ID [2020] 091) for this retrospective study was obtained from CAPA and the institutional review board of The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Variables Analyzed

All patients in the CAPA database were diagnosed with acromegaly in accordance with established guidelines (**Box 1**).[8] Diagnostic factors include classic signs and symptoms, biochemical assays, and radiographic identification of a pituitary tumor (**Figure 1**).

> **Box 1 | Diagnostic and biochemical remission criteria for acromegaly**
>
> ***Diagnostic criteria***
>
> - Classic signs and symptoms (**Figure 1**)
> - Endocrinological assay: fasting growth hormone (GH) > 2.5 µg/L, glucose GH inhibition test with lowest GH > 1 µg/L, and insulin-like growth factor 1 (IGF-1) level higher than the normal range of age- and sex-matched healthy individuals
> - Radiographic identification of a pituitary tumor on computed tomography (CT), high-resolution magnetic resonance imaging (MRI), or dynamic contrast-enhanced MRI of the sellar region
> - Pituitary hormone aberrancies: abnormal levels in prolactin (PRL), follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and/or adrenocorticotropic hormone (ACTH)
>
> ***Biochemical remission criteria***
>
> - Random serum GH < 2.5 µg/L, glucose GH inhibition test with GH < 1 µg/L
> - Normalized serum IGF-1 level

Radiographic features

Imaging was reviewed by either an attending neurosurgeon or neuroradiologist. Cavernous sinus invasion was classified using the Knosp Grading System.[9] Tumor invasion was defined as Knosp grades 3 & 4 (evidence of tumor crossing the lateral border of the cavernous carotid artery on coronal MRI image), while lack of invasion was defined as a Knosp score of 0 to 2 (margin of tumor medial to the lateral border of cavernous carotid artery).[9,10]

Tumor size was classified into three categories: microadenomas (maximum diameter <1 cm), macroadenomas (1-4 cm), and giant adenomas (≥4 cm).[11]

Location of residence

The geographic grouping was performed based on the Yicai Media Group (https://www.yicai.com) stratification of Chinese cities and towns into 5 tiers, which we adapted to classify patient residence into the following categories based on population density and size of economy: large city, medium city, and small city/town.

Insurance coverage

There are three insurance schemes in China, including the urban employee-based basic medical insurance scheme (UEBMI; launched in 1998), urban resident-based basic medical insurance scheme (URBMI; launched in 2007), and rural new cooperative medical scheme (NCMS; launched in 2003), which is intended to provide affordable health insurance for the poor and improve the equity of health services in rural China.[12] In general, UEBMI covers a broader array of medical services than URBMI, with NCMS having the least robust coverage.

Treatment

Primary treatment modalities included medication, radiotherapy, or surgery, which comprised of microscopic endonasal, endoscopic endonasal, or transcranial surgery (**Figure 2**). All surgical specimens were analyzed using immunohistopathology. Patients who did not achieve initial biochemical remission received one of the following secondary treatments: repeat surgery, radiotherapy, medication, or combined-therapy.

Outcome Measures

The primary outcome of interest was biochemical remission at 3 months postoperatively. The criteria for postoperative biochemical remission after surgery for acromegaly were based on the established guidelines (**Box 1**).[8]

Statistical Analysis

Baseline characteristics were described using mean ± standard deviation (SD), median (interquartile range, IQR), or frequency (proportion) according to the variable type. Group differences were compared using the two-sample Student's t-test (parametric) or Mann-Whitney U-test (nonparametric) for continuous variables, and Pearson's chi-squared test (two-tailed) or Fisher's exact test for categorical variables, as appropriate. The family discovery rate (FDR) correction was performed across all univariate analyses to adjust for multiple testing. A purposeful selection approach to multivariate logistic regression analysis was performed to determine the independent predictors of biochemical remission at 3 months postoperatively in patients with acromegaly. Results were presented as odds ratios (ORs) with 95% confidence intervals (CI). The collinearity between variables was explored and evaluated by the variance influence factor (VIF) in the regression analysis. Significance was set at $p < 0.05$ (two-tailed). All statistical analyses were performed using statistical packages in R (https://www.R-project.org/).[13]

Results

Cohort

We retrospectively analyzed presenting features, imaging, and clinical outcomes for 575 acromegaly patients (mean age 37.3±10.3 years; 59% women) from the multi-institutional patient-reported CAPA database. The median time from symptom onset to diagnosis was 5 years (range: 1-10 years). The most common clinical symptoms and signs at presentation were enlarged nose and prognathism (97.4%), overgrowth of extremities (93.4%), menstrual disturbance in females (66.8%), snoring or sleep apnea (62.3%), headache (58.4%), and hypertrichosis (56.2%) (**Table 1, Figure 1**). Visual field abnormalities, resulting from tumor mass effect, occurred in 49.2% of patients. Apoplexy occurred in 9.6%, producing tumor mass effect. Other comorbidities associated with acromegaly were reported as follows: cardiovascular disease (40.0%), impaired glucose tolerance (31.0%), osteoporosis (22.6%), colonic polyps (16.3%), arthritis (15.8%), and colon cancer (0.7%).

Large and giant tumors dominated this cohort, with 73.2% being macroadenomas, 10.1% being giant adenomas, and 16.7% being microadenomas (**Table 2, Figure 3A**). Headache was more frequently reported in patients with giant adenomas (70.7%) than those with microadenomas (51.1%, p=0.03) or macroadenomas (58.4%, p=0.06). Consistent with the prevalence of large tumors in this cohort, two-thirds of the tumors demonstrated cavernous sinus invasion (**Table 2, Figure 3A**).

The majority of patients lived in large cities (43.8%), while only 20.4% of acromegaly patients were from small cities/towns. The urban employer-driven UEBMI scheme was the most prevalent insurance coverage in our cohort (63.7%), followed by the urban resident NCMS (22.6%) and the rural URBMI (13.7%) plans (**Table 1**).

Median follow-up after the initial diagnosis was 54 months (range 6-295 months), while median follow-up after initial treatment was 32 months (range 3-256 months), suggesting an average of 19 months interval delay between diagnosis and treatment.

Endocrinological Status

Among 575 acromegaly patients, the mean levels of GH and IGF-1 prior to surgery were 26.8 μg/L and 781.5 μg/L respectively. Mean preoperative GH level was significantly higher in patients with macroadenomas (27.3 μg/L) and giant adenomas (36.8 μg/L) compared to those with microadenomas (18.5 μg/L) (both $p<0.001$) (**Figure 3B**). Additionally, tumors with cavernous sinus invasion exhibited significantly higher median GH levels than those without invasion (28.7 μg/L vs. 23.3 μg/L, $p<0.001$) (**Figure 3C**).

Treatment

546 patients (95%) received surgery as their initial treatment, while 21 patients (3.7%) received medical therapy alone and 8 patients (1.3%) received upfront radiation (**Figure 2**). The most common operative approach was endoscopic endonasal transsphenoidal (94.9%), with transcranial surgery (5.1% of cases) mostly reserved for larger tumors with a greater extent of invasiveness. The mean age of patients who received either medication or radiation only was 49 years (range 32-70 years), compared to a mean of 37 years (range 16-76 years) in patients who underwent surgery ($p<0.001$). For patients receiving medication alone, mean GH levels trended lower than that of patients who underwent surgery (19.7 vs. 27.0 μg/L, respectively; p=0.036).

Surgical Outcome

Among the 546 patients who underwent initial surgical resection, histopathology confirmed immunopositivity for GH alone in 81.5%, concurrent GH and prolactin staining in 13.7%, and the presence of additional hormone expression along with GH in the remaining (4.8%) (**Table 2**). Tumors that stained for both GH and prolactin were more likely than solely GH-staining tumors to be invasive (78.7% vs. 61.1%, respectively; p=0.003).[14] Moreover, the most common postoperative complication was postoperative hyponatremia (sodium <135 mmol/L) (26.0%), followed by diabetes insipidus (18.5%), cerebrospinal fluid leak (6.8%), meningitis (0.4%). One case of internal carotid artery (ICA) injury was reported.

At three months after surgery, 209 (38.3%) patients had achieved biochemical remission (**Table 3, Figure 2**). More aggressive tumors were associated with a lower likelihood of

remission at 3 months. Specifically, higher pre-operative GH levels, larger tumors, and the presence of cavernous sinus invasion were all significantly associated with lack of remission (p=0.003, p<0.001, p<0.001, respectively). Although biochemical remission was observed in 63.6% of microadenoma patients, it was only observed in 12.3% of patients with giant adenomas. Similarly, 57.1% of cases with Knosp grade 0-2 experienced remission, compared to only 27.7% of Knosp grade 3-4 tumors.

Multivariate logistic regression analysis showed that preoperative GH levels >28 μg/L (highest tertile of our cohort) compared to pre-operative GH level <12 μg/L (lowest tertile in our cohort) decreased the odds of remission at 3 months after surgery by 44% (p=0.016). Additionally, having a macroadenoma or giant adenoma decreased the odds of remission by 43% (p=0.041) and 83% (p=0.0005), respectively, compared to having a microadenoma. Similarly, tumors with a Knosp score of 3-4 had 61% less odds of biochemical remission at 3 months than those with a Knosp score of 0-2 (p<0.0001). Adjusted for age, preoperative GH level, tumor size, and Knosp score, preoperative medication usage more than doubled the odds of biochemical remission (OR=2.16, p=0.0008) (**Figure 4**). The reduction of statistical power through a high correlation between two or more explanatory variables (multicollinearity) was not observed in our regression model (maximum VIF=1.3).

Patient age, sex, disease duration, city type of residence, insurance type, apoplexy, surgical approach (microscopic endonasal, endoscopic endonasal, or transcranial), and plurihormonal expression were not significantly associated with postoperative biochemical remission in this cohort.

Discussion

We present the clinical characteristics of over 500 acromegaly patients in China and observe tumor and treatment factors strongly associated with disease control at three months after surgery or other definitive treatment. Our study represents the largest analysis of clinical features and postoperative outcomes of acromegaly in China, and also constitutes the first application of the CAPA database for clinical research. We observed a 3-month postoperative remission rate of 38.3%, with the likelihood of disease control strongly influenced by the preoperative GH level, tumor size, and tumor invasiveness as indicated by the Knosp grade.

Despite China's vast population size, medical studies on acromegaly remain sparse, particularly in English-language journals. The earliest record of a surgical case of acromegaly in China dates back to 1929, when the first patient was operated on using transcranial surgery at the Peking Union Medical College Hospital (records endure in archives of the hospital library). Early published studies from China were mostly case series and smaller cohorts. More recently, a single-institution retrospective analysis of 358 Chinese acromegalic patients found the GH remission rate to be 37.3% in patients with invasive macroadenomas without receipt of preoperative somatostatin analogs as compared to 56.4% among those with pre-operative medical treatment.[15] We drew upon the power of a patient-reported database to expand on the clinical experience in the diagnosis and treatment of acromegaly in China across multiple institutions.

Clinical characteristics

Although the most commonly reported symptoms were physical changes involving the
face (97.4%) and extremities (93.4%), similar to previously published series,[2,16] the detection of
such changes may occur in a delayed fashion given the typically insidious onset over decades.
Additionally, dental malocclusion, median thenar neuropathy (carpal tunnel syndrome), change
in shoe size or ring size, and skin tags may be overlooked signs of acromegaly. Sleep apnea,
headache, and hyperhidrosis were observed in over half of patients, in addition to menstrual
disturbances in two-thirds of female patients. These, among other common non-physical,
symptoms should prompt closer inspection for physical signs of acromegaly and consideration
for endocrinological evaluation, including assaying IGF-1 determinations.
Analogous to other studies,[2] headache was commonly reported in our cohort (58.4%), as
was the relationship between larger tumors and increased prevalence of headache. Although
visual field deficit clearly triggers an alarm for a compressive etiology involving the optic
apparatus, 52.5% of patients with macroadenomas did not report any subjective visual
impairment. Clinical concern for a large pituitary tumor, as in aggressive acromegaly cases,
should prompt formal neuro-ophthalmologic evaluation.
Acromegaly is associated with premature mortality.[17,18] Older age at diagnosis, increased
time from symptom onset to diagnosis, higher GH levels after treatment, and cardiovascular risk
factors are independent predictors of early mortality.[18] Forty percent of patients in this cohort
reported cardiovascular symptoms or disease, including heart palpitations, arrhythmias (e.g.,
atrial fibrillation and heart block), structural heart diseases (e.g., cardiomyopathy and valvular
disease), and hypertension. These findings, when viewed in light of the fact that the mean age of
our cohort was only 37.3 years, underscores the strikingly significant impact of acromegaly on
cardiovascular health.[19] Furthermore, the high incidence of impaired glucose tolerance (diabetes
mellitus), osteoporosis, colonic polyps, and arthritis/arthropathies observed also supports the
need for diligent and careful screening by providers, as outlined by the Endocrine Society
Clinical Practice Guidelines for acromegaly.[1] Early diagnosis in conjunction with effective
treatment and persistent control/screening of comorbidities are paramount to decreasing the
morbidity and mortality associated with this condition.
317
318 *Factors influencing biochemical remission*
319
The 38.3% biochemical remission rate at 3-months after surgery for a GH secreting
tumor in our cohort is relatively low compared to other reports in the literature.[20,21] This may
reflect the high proportion of large and invasive tumors encompassed by our cohort. Additionally,
cultural factors and health literacy for neuroendocrinological diseases may contribute to a delay
in seeking medical care, resulting in the disease progression. In addition, 1 in 5 patients in our
cohort was from a small city or town, which may further delay access to medical care and
endocrinological evaluation. Although we did not observe a statistically significant impact of
socioeconomic or insurance status on the likelihood of biochemical remission after surgery for
acromegaly in this patient-reported cohort, further investigations are merited to improve the
delay between diagnosis and treatment, and also potential delays in the initial recognition of
acromegaly, especially amongst individuals with geographical and financial barriers.
Preoperative clinical and biochemical characteristics could impact the likelihood of
biochemical remission, including age at diagnosis,[22] gender,[22] preoperative serum levels of GH
and IGF-1,[20,23–27] tumor size,[20,24,28,29] preoperative medication usage,[15,21] tumor
invasiveness,[20,24,27–31] and histological pathology (Ki-67, somatostatin receptor subtype 2

expression, AIP expression, and granularity).[24,30] Similar to other studies, our analysis also
revealed that larger tumors (giant and macroadenomas) were less likely than small tumors to
enter biochemical remission at 3 months. Further, patients with invasive tumors and higher
preoperative GH levels were less likely to attain remission. Given that aggressive tumors were
shown to be less likely to enter biochemical remission postoperatively, early surgical
intervention should be instituted to halt further progression of disease.[32]
Pharmaceutical treatment, including somatostatin receptor ligands (SRLs), growth
hormone receptor antagonists, and dopamine agonists (DA), have shown to have a beneficial
impact on surgical outcomes as both neoadjuvant and adjuvant therapy,[15,21] which was also
demonstrated by our team.[33] In particular, administration of somatostatin analogs prior to surgery
is associated with higher endocrinological remission than adjuvant treatment alone.[15,34–37]
Likewise, the use of preoperative medical treatment more than doubled the odds of remission in
our cohort.
348

Limitations

Our study strengthens the insight into the patterns of care and results of treatment for
acromegaly in China. The vast heterogeneity in the regional economy, insurance coverage,
education, health literacy, and accessibility of medical care, however, may limit the
generalizability of these results to all acromegaly patients in China. The self-reported nature of
the CAPA database further contributed to a significant burden of missing data at longer follow-
up dates. This prevented assessment of the durability of biochemical remission and motivates
refining strategies for systematic clinical follow-up in diverse and geographically dispersed
populations such as in China. Finally, as evidenced by the low median age of our cohort, the
majority of patients who contributed to this database through online submission were young,
likely reflecting age-related biases in adopting an electronic reporting platform. Strategies to
expand access and ease of data accrual from more diverse populations, both in demographics and
age, may further diversify the value of this clinical database in the future.

362
Conclusions
We present the largest nation-wide analysis of clinical features and surgical outcomes of
acromegaly patients in China, driven from a patient-reported database. We highlight that higher
preoperative GH levels, giant adenomas, and greater extent of tumor invasiveness are associated
with a lower likelihood of biochemical remission at 3-months after surgery, while preoperative
medical therapy increases the chance of remission. Importantly, we have established the
effectiveness and potential of a patient-reported database in advancing neuroendocrinological
research.
371
372
373

374   **Disclosures**
375   The authors report no conflict of interest concerning the materials or methods used in this study
376   or the findings specified in this paper.
377
Acknowledgments

This work was supported by the funding to SY through the Chinese Postdoctoral Science
Foundation (2019M663271) and the Chinese Scholarship Council (201808440461), Guangzhou
Science and Technology Project (201704020085) to HJW, and the National Institute of Health
(NIH) Ruth L. Kirschstein National Research Service Award (T32DC000038-27) to LZ.
The authors would like to thank all the patients and families and their providers who collaborated
with the establishment of CAPA database. We are grateful for the collaboration with the Chinese
Association of Patients with Acromegaly (CAPA). We also thank Mr. Hao Luo (Warwick
Business School, United Kingdom) for creating the China heat-map for the geographic
distribution of acromegaly patients.
388

389 Author Contributions

Conception and design: WL Chen, HJ Wang, and WL Bi. Acquisition of data: WL Chen and HJ
Wang. Analysis and Interpretation of data: all authors. Drafting the article: S Yao, S Tavakol,
and WL Bi. Critically revising the article: S Yao, S Tavakol, F Akter, MP Catalino, ER Laws,
WL Bi, and HJ Wang. Reviewed submitted version of manuscript: all authors. Approved the
final version of manuscript on behalf of all authors: HJ Wang. Statistical analysis: S Yao, S
Tavakol, WL Bi. Graphic visualization: S Yao. Clinical diagnosis and radiological identification:
WL Chen and ZG Mao. Administrative/technical/material support: WL Chen, ZG Mao, YH Zhu,
and HJ Wang.
Study supervision: HJ Wang and WL Bi.
399

References:

1. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical
Practice Guideline. *J Clin Endocrinol Metab*. 2014;99(11):3933-3951. doi:10.1210/jc.2014-
2700

2. Colao A, Grasso LFS, Giustina A, et al. Acromegaly. *Nat Rev Dis Primers*. 2019;5(1):20.
doi:10.1038/s41572-019-0071-6

3. Cook DM, Ezzat S, Katznelson L, et al. AACE Medical Guidelines for Clinical Practice for
the diagnosis and treatment of acromegaly. *Endocr Pract*. 2004;10(3):213-225.
doi:10.4158/EP.10.3.213

4. Abreu A, Tovar AP, Castellanos R, et al. Challenges in the diagnosis and management of
acromegaly: a focus on comorbidities. *Pituitary*. 2016;19:448-457. doi:10.1007/s11102-
016-0725-2

5. Melmed S. Acromegaly. *New England Journal of Medicine*. 2006;355(24):2558-2573.
doi:10.1056/NEJMra062453

6. Lugo G, Pena L, Cordido F. Clinical Manifestations and Diagnosis of Acromegaly. *Int J*
Endocrinol. 2012;2012. doi:10.1155/2012/540398

7. Chanson P, Salenave S. Acromegaly. *Orphanet J Rare Dis*. 2008;3:17. doi:10.1186/1750-
1172-3-17

8. Chinese Society of Endocrinology, Chinese Neurosurgical Society, and Chinese Pituitary
Adenoma Cooperative Group. Chinese guideline of acromegaly diagnosis and management
(2013). *Natl Med J China*. 2013;93(27):2106-2111. doi:10.3760/cma.j.issn.0376-
2491.2013.27.005

9. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous
sinus space: a magnetic resonance imaging classification compared with surgical findings.
Neurosurgery. 1993;33(4):610-617. doi:10.1227/00006123-199310000-00008

10. Mooney MA, Hardesty DA, Sheehy JP, et al. Interrater and intrarater reliability of the Knosp
scale for pituitary adenoma grading. *Journal of Neurosurgery*. 2017;126(5):1714-1719.
doi:10.3171/2016.3.JNS153044

11. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. *JAMA*.
2017;317(5):516-524. doi:10.1001/jama.2016.19699

12. Meng Q, Fang H, Liu X, Yuan B, Xu J. Consolidating the social health insurance schemes in
China: towards an equitable and efficient health system. *The Lancet*.
2015;386(10002):1484-1492. doi:10.1016/S0140-6736(15)00342-6

13. R Core Team. R: A language and environmentfor statistical computing. *R Foundation for*
Statistical Computing, Vienna, Austria. Published online 2019. https://www.R-project.org/.

14. Rick J, Jahangiri A, Flanigan PM, et al. Growth hormone and prolactin-staining tumors
causing acromegaly: a retrospective review of clinical presentations and surgical outcomes.
Journal of Neurosurgery. 2018;131(1):147-153. doi:10.3171/2018.4.JNS18230

15. Duan L, Zhu H, Xing B, Gu F. Prolonged preoperative treatment of acromegaly with
Somatostatin analogs may improve surgical outcome in patients with invasive pituitary
macroadenoma (Knosp grades 1–3): a retrospective cohort study conducted at a single
center. *BMC Endocr Disord*. 2017;17(1):55. doi:10.1186/s12902-017-0205-3

16. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of
acromegaly, a nationwide study from 1955 through 2013. *Pituitary*. 2015;18(6):803-807.
doi:10.1007/s11102-015-0655-4

17. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in
Acromegaly: A Metaanalysis. *J Clin Endocrinol Metab*. 2008;93(1):61-67.
doi:10.1210/jc.2007-1191

18. Holdaway IM, Rajasoorya RC, Gamble GD. Factors Influencing Mortality in Acromegaly. *J*
Clin Endocrinol Metab. 2004;89(2):667-674. doi:10.1210/jc.2003-031199

19. Guo X, Gao L, Zhang S, et al. Cardiovascular System Changes and Related Risk Factors in
Acromegaly Patients: A Case-Control Study. *Int J Endocrinol*. 2015;2015:573643.
doi:10.1155/2015/573643

20. Jane JA, Starke RM, Elzoghby MA, et al. Endoscopic Transsphenoidal Surgery for
Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome.
J Clin Endocrinol Metab. 2011;96(9):2732-2740. doi:10.1210/jc.2011-0554

21. Yang C, Li G, Jiang S, Bao X, Wang R. Preoperative Somatostatin Analogues in Patients
with Newly-diagnosed Acromegaly: A Systematic Review and Meta-analysis of
Comparative Studies. *Sci Rep*. 2019;9(1):1-9. doi:10.1038/s41598-019-50639-6

22. Park SH, Ku CR, Moon JH, Kim EH, Kim SH, Lee EJ. Age- and Sex-Specific Differences as
Predictors of Surgical Remission Among Patients With Acromegaly. *J Clin Endocrinol*
Metab. 2018;103(3):909-916. doi:10.1210/jc.2017-01844

23. Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving
criteria for post-operative biochemical remission of acromegaly: can we achieve a
definitive cure? An audit of surgical results on a large series and a review of the literature.
Endocr Relat Cancer. 2003;10(4):611-619. doi:10.1677/erc.0.0100611

24. Fernandez-Rodriguez E, Casanueva FF, Bernabeu I. Update on prognostic factors in
acromegaly: Is a risk score possible? *Pituitary*. 2015;18(3):431-440. doi:10.1007/s11102-
014-0574-9

25. Kaltsas GA, Isidori AM, Florakis D, et al. Predictors of the outcome of surgical treatment in
acromegaly and the value of the mean growth hormone day curve in assessing
postoperative disease activity. *J Clin Endocrinol Metab*. 2001;86(4):1645-1652.
doi:10.1210/jcem.86.4.7398

26. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of Survival in Treated
Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I
Measurements. *J Clin Endocrinol Metab*. 2004;89(6):2789-2796. doi:10.1210/jc.2003-
032041

27. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal
adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome
analysis and determinants of failure. *J Neurosurg*. 1993;78(2):205-215.
doi:10.3171/jns.1993.78.2.0205

28. Sun H, Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Factors Associated
with Biochemical Remission after Microscopic Transsphenoidal Surgery for Acromegaly. *J
Neurol Surg B*. 2014;75(1):47-52. doi:10.1055/s-0033-1354578

29. Laws ER, Piepgras DG, Randall RV, Abboud CF. Neurosurgical management of acromegaly.
Results in 82 patients treated between 1972 and 1977. *J Neurosurg*. 1979;50(4):454-461.
doi:10.3171/jns.1979.50.4.0454

30. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with
acromegaly using current criteria of biochemical 'cure.' *European Journal of
Endocrinology*. 2005;152(3):379-387. doi:10.1530/eje.1.01863

31. Antunes X, Ventura N, Camilo GB, et al. Predictors of surgical outcome and early criteria of
remission in acromegaly. *Endocrine*. 2018;60(3):415-422. doi:10.1007/s12020-018-1590-8

32. Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. *Rev Endocr
Metab Disord*. 2008;9(1):67-70. doi:10.1007/s11154-007-9064-y

33. Mao Z, Zhu Y, Tang H, et al. Preoperative lanreotide treatment in acromegalic patients with
macroadenomas increases short-term postoperative cure rates: a prospective, randomised
trial. *European Journal of Endocrinology*. 2010;162(4):661-666. doi:10.1530/EJE-09-0908

34. Nunes VS, Correa JMS, Puga MES, Silva EMK, Boguszewski CL. Preoperative
somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed
acromegaly patients: a systematic review and meta-analysis using the GRADE system.
Pituitary. 2015;18(4):500-508. doi:10.1007/s11102-014-0602-9

35. Albarel F, Castinetti F, Morange I, et al. Pre-surgical medical treatment, a major prognostic
factor for long-term remission in acromegaly. *Pituitary*. 2018;21(6):615-623.
doi:10.1007/s11102-018-0916-0

36. Shen M, Shou X, Wang Y, et al. Effect of presurgical long-acting octreotide treatment in
acromegaly patients with invasive pituitary macroadenomas: a prospective randomized
study. *Endocr J*. 2010;57(12):1035-1044. doi:10.1507/endocrj.k10e-203

37. Vance ML, Laws ER. Role of medical therapy in the management of acromegaly.
Neurosurgery. 2005;56(5):877-885.

Table 1. Demographics and clinical presentation (N=575)

Categories	Distribution
Mean age (years), mean ± SD	37.3 ± 10.3
Male / Female	235/340
Disease duration (years), median (IQR)	5 (2.5-8.0)
Follow-up after initial diagnosis (months), median (IQR)	54 (30-86)
Follow-up after initial treatment (months), median (IQR)	32 (13-61)
Clinical symptoms and signs, n (%)	
Enlarged nose and prognathism	560 (97.4)
Overgrowth of extremities	537 (93.4)
Menstrual disturbance (female)	227 (66.8)
Snoring or sleep apnea	358 (62.3)
Headache	336 (58.4)
Hyperhidrosis	323 (56.2)
Hypertrophy of frontal bones	287 (49.9)
Visual field abnormalities	283 (49.2)
Cardiovascular disease	230 (40.0)
Impaired glucose tolerance	178 (31.0)
Hypertrichosis	197 (34.3)
Jaw malocclusion	139 (24.2)
Osteoporosis	130 (22.6)
Colonic polyps	94 (16.3)
Arthritis	91 (15.8)
Galactorrhea	88 (15.3)
Colonic cancer	4 (0.7%)
Resident area	
Large city	252 (43.8)
Medium city	206 (35.8)
Small city/town	117 (20.4)
Insurance type	
Urban Employee Basic Medical Insurance	366 (63.7)
New Cooperative Medical Scheme	130 (22.6)
Urban Resident Basic Medical Insurance	79 (13.7)

Abbreviations: IQR, interquartile range; SD, standard deviation.

Table 2. Tumor characteristics and treatment (N=575)

Categories	Distribution
Initial biochemical levels	
GH (µg/L), mean ± SD	26.8 ± 26.1
IGF-1 (µg/L), mean ± SD	781.5 ± 290.8
3-month biochemical levels	
GH (µg/L), median, (IQR)	4.32 (1.3 – 11.2)
IGF-1 (µg/L), mean ± SD	572.3 ± 289.7
Tumor size, n (%)	
Microadenomas (< 1cm)	96 (16.7)
Macroadenomas (1 - 4cm)	421 (73.2)
Giant adenomas (≥ 4cm)	58 (10.1)
Knosp score, n (%)	
Score 0	58 (10.1)
Score 1	110 (19.1)
Score 2	54 (9.4)
Score 3	270 (47.0)
Score 4	83 (14.4)
Apoplexy, n (%)	55 (9.6)
Preoperative medication, n (%)	125 (21.7)
Initial treatment, n (%)	
Radiotherapy	8 (1.3)
Medication	21 (3.7)
Surgery	546 (95)
Pathology, n (%)	
GH	445 (81.5)
GH + PRL	75 (13.7)
GH + TSH	5 (0.9)
GH + ACTH	3 (0.6)
GH + (> 2 hormones)	18 (3.3)
Postoperative complications, n[*] (%)	
Transient hyponatremia	142 (26.0)
Transient diabetes insipidus	101 (18.5)
Cerebrospinal fluid leak	37 (6.8)
Meningitis	2 (0.4)
ICA injury (intraoperative)	1 (0.2)

516   **Abbreviations:** ACTH, Adrenocorticotropic hormone; GH, growth hormone; ICA, intracranial artery;

517   IGF-1, insulin-like growth factor 1; IQR, interquartile range; PRL, prolactin; SD, standard deviation;

518   TSH, thyroid stimulating hormone.

Table 3. Comparison of demographics and clinical presentation between 3-month non-remission and remission cases

Categories	Surgical remission		P-value [d]
	No (n = 337)	Yes (n = 209)	
Age (years), mean ± SD	36.0 ± 9.7	38.2 ± 10.1	0.08
Sex			0.966
Male	137 (62.0)	84 (38.0)	
Female	200 (61.5)	125 (39.5)	
Disease duration (years), median (IQR)	4 (2 - 8)	5 (2-8)	0.361
Initial GH levels (µg/L), median (IQR)	20.0 (12.0 – 40.0)	14.6 (10.2 – 29.9)	**0.003**
Tumor size, n (%)			**< 0.001**
Microadenomas	32 (36.4)	56 (63.6)	
Macroadenomas	255 (63.6)	146 (36.4)	
Giant adenomas	50 (87.7)	7 (12.3)	
Knosp score, n (%)			**< 0.001**
0-2	84 (42.9)	112 (57.1)	
3-4	253 (72.3)	97 (27.7)	
Apoplexy, n (%)	31 (62.0)	19 (38.0)	0.966
Preoperative medication, n (%)	67 (53.6)	58 (46.4)	0.08
Surgical approach, n (%)			0.262
Transcranial surgery	22 (78.6)	6 (21.4)	
Microscopic TSS	131 (62.7)	78 (37.3)	
Endoscopic TSS	184 (59.5)	125 (40.5)	
Pathology, n (%)			0.727
GH	269 (60.5)	176 (39.5)	
GH + ACTH	2 (66.7)	1 (33.3)	
GH + PRL	49 (65.3)	26 (34.7)	
GH + TSH	3 (60.0)	2 (40.0)	
GH + (> 2 hormones)	14 (77.8)	4 (22.2)	
City type of residence			0.521
Large city	138 (58.7)	97 (41.3)	
Medium city	131 (65.5)	69 (34.5)	
Small city/town	68 (61.3)	43 (38.7)	
Insurance type			0.721
Urban Employee Basic Medical Insurance	211 (61.9)	130 (38.1)	
New Cooperative Medical Scheme	83 (64.3)	46 (35.7)	
Urban Resident Basic Medical Insurance	43 (56.6)	33 (43.4)	

[d] **FDR correction**

Abbreviations: ACTH, Adrenocorticotropic hormone; eTSS, endonasal transsphenoidal surgery; GH, growth hormone; IQR, interquartile range; PRL, prolactin; SD, standard deviation; TSH, thyroid stimulating hormone.

525   **Table 4. Multivariate predictors of 3-month surgical remission in acromegaly patients**

Variable	Logistic regression analysis		
	OR	95% CI	P value
Preoperative GH Level (µg/L)[a]			
12 – 28	0.61	0.39 - 0.96	**0.031**
> 28	0.56	0.35 - 0.90	**0.016**
Tumor size[b]			
Macroadenoma	0.57	0.33 - 0.97	**0.041**
Giant adenoma	0.17	0.06 - 0.44	**0.0005**
Knosp score: 3-4[c]	0.39	0.25 - 0.59	**< 0.0001**
Preoperative medication usage	2.16	1.38 - 3.39	**0.0008**

527
528   [a]Reference level <12 µg/L
529   [b]Reference: Microadenoma
530   [c]Reference: Knosp score 0-2
531   **Abbreviations:** CI, confidence interval; GH, growth hormone; OR, odds ratio.

Figure Legends

Figure 1. Classic clinical signs and symptoms of acromegaly.

Figure 2. Treatment pathways among patients in the CAPA cohort.

Figure 3. (A) Distribution of cases by Knosp classification and tumor size. (B & C) The association of preoperative growth hormone (GH) levels compared with tumor size and Knosp score.

Figure 4. Adjusted odds ratios (OR) and 95% confidence intervals for predictors of biochemical remission at 3 months (p<0.05). [a]Reference level: <12 μg/L; [b]Reference: Microadenoma; [c]Reference: Knosp score 0-2.

Supplemental Material S1. The geographic distribution of acromegaly patients in the China Acromegaly Patient Association (CAPA) database between 1998 and 2018, across 23 provinces, 4 autonomous regions, 4 municipalities, and 2 Special Administrative Regions (Hong Kong and Macau) in China.

Physical changes
- Enlarged nose and prognatism
- Overgrowth of extremities
- Prominence of the brow
- Jaw malocclusion
- Acral overgrowth
- Soft-tissue hypertrophy
- Hyperhidrosis
- Thickened skin

Local tumor effects
- Headache
- Visual impairments
- Increased intracranial pressure
- Hypopituitarism
- Apoplexy

Respiratory complications
- Upper airway obstruction
- Ventilatory dysfunction
- Sleep apnea
- Excessive snoring

Cardiovascular complications
- Hypertension
- Cardiomyopathy
- Arrhythmias
- Congestive heart failure
- Coronary heart disease
- Valve disease
- Atherosclerosis
- Stroke

Metabolism and endocrine complications
- Impaired glucose tolerance
- Insulin resistance and hyperinsulinemia
- Diabetes mellitus
- Other endocrinologic derangements

Reproductive disorders
- Menstrual disturbance
- Galactorrhea
- Decreased libido

Gastrointestinal complications
- Colonic polyps
- Colonic cancer

Skeletal system complications
- Carpal tunnel syndrome
- Arthropathy
- Osteoporosis
- Vertebral fractures
- Thickened articular cartilage